2019 Progress In Ht-1 Newborn Screening
Sobi presented an update on the state of newborn screening for Hereditary Tyrosinemia Type 1 (HT-1) in the United States during the Association of Public Health Laboratories’ (APHL) 2019 Newborn Screening and Genetic Testing Symposium, April 7-10 in Chicago.
A 2015 Sobi-sponsored study showed 78% (39 of 50) of states used SUAC as a primary marker for HT-1 newborn screening.5 The new data presented at the APHL symposium found that progress has been made in the past three years, with 92% (46 of 50) of states implementing the use of SUAC for HT-1 detection in 2018. Of the remaining four states still using tyrosine for detection (New Jersey, Maryland, Oklahoma and West Virginia), all are attempting to implement SUAC detection tests in the next year.
Read the full press release.